RESUMEN
BACKGROUND: US iodine intake, estimated from the median urinary iodine concentration of population representative data, has declined by half since the 1970s, which is problematic because maternal iodine intake is critical for fetal neurodevelopment. Relying on median urinary concentrations to assess iodine intake of populations is standard practice but does not describe the number of individuals with insufficient intake. Prevalence estimates of inadequate and excessive intake are better for informing public health applications but require multiple urine samples per person; such estimates have been generated in pediatric populations but not yet among pregnant women. OBJECTIVE: Our aims were as follows: (1) to assess median urinary iodine concentrations across pregnancy for comparison with national data and (2) to estimate the prevalence of inadequate and excessive iodine intake among pregnant women in mid-Michigan. STUDY DESIGN: Data were collected from 2008 to 2015 as part of a prospective pregnancy cohort in which women were enrolled at their first prenatal clinic visit. Few exclusion criteria (<18 years or non-English speaking) resulted in a sample of women generally representative of the local community, unselected for any specific health conditions. Urine specimens were obtained as close as practicable to at least 1 specimen per trimester during routine prenatal care throughout pregnancy (n=1-6 specimens per woman) and stored at -80°C until urinary iodine was measured to estimate the iodine intake (n=1014 specimens from 464 women). We assessed urinary iodine across pregnancy by each gestational week of pregnancy and by trimester. We used multiple urine specimens per woman, accounted for within-person variability, performed data transformation to approximate normality, and estimated the prevalence of inadequate and excessive iodine intake using a method commonly employed for assessment of nutrient status. RESULTS: Maternal characteristics reflected the local population in racial and ethnic diversity and socioeconomic status as follows: 53% non-Hispanic white, 22% non-Hispanic black, and 16% Hispanic; 48% had less than or equal to high school education and 71% had an annual income of <$25,000. Median urinary iodine concentrations in the first, second, and third trimester-including some women contributing more than 1 specimen per trimester-were 171 µg/L (n=305 specimens), 181 µg/L (n=366 specimens), and 179 µg/L (n=343 specimens), respectively, with no significant difference by trimester (P=.50, Kruskal-Wallis test for equality of medians). The estimated prevalence of inadequate and excessive iodine intake was 23% and <1%, respectively. CONCLUSION: Median urinary iodine concentrations in each trimester were above the World Health Organization cutoff of 150 µg/L, indicating iodine sufficiency at the group level across pregnancy. However, the estimated prevalence of inadequate iodine intake was substantial at 23%, whereas prevalence of excessive intake was <1%, indicating a need for at least some women to increase consumption of iodine during pregnancy. The American Thyroid Association, the Endocrine Society, and the American Academy of Pediatrics recommend that all pregnant and lactating women receive a daily multivitamin or mineral supplement that contains 150 µg of iodine. The data presented here should encourage the collection of similar data from additional US population samples for the purpose of informing the American College of Obstetricians and Gynecologists' own potential recommendations for prenatal iodine supplementation.
Asunto(s)
Enfermedades Carenciales/epidemiología , Suplementos Dietéticos , Yodo/deficiencia , Necesidades Nutricionales , Complicaciones del Embarazo/epidemiología , Atención Prenatal , Adulto , Estudios de Cohortes , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/orina , Femenino , Humanos , Yodo/administración & dosificación , Yodo/orina , Michigan/epidemiología , Embarazo , Complicaciones del Embarazo/dietoterapia , Complicaciones del Embarazo/orina , Trimestres del Embarazo , Estudios Prospectivos , Estados Unidos/epidemiología , Adulto JovenRESUMEN
Contents 699 I. 699 II. 700 III. 700 IV. 706 V. 707 VI. 714 714 References 714 SUMMARY: Plants make substantial contributions to our health through our diets, providing macronutrients for energy and growth as well as essential vitamins and phytonutrients that protect us from chronic diseases. Imbalances in our food can lead to deficiency diseases or obesity and associated metabolic disorders, increased risk of cardiovascular diseases and cancer. Nutritional security is now a global challenge which can be addressed, at least in part, through plant metabolic engineering for nutritional improvement of foods that are accessible to and eaten by many. We review the progress that has been made in nutritional enhancement of foods, both improvements through breeding and through biotechnology and the engineering principles on which increased phytonutrient levels are based. We also consider the evidence, where available, that such foods do enhance health and protect against chronic diseases.
Asunto(s)
Productos Agrícolas , Enfermedades Carenciales/prevención & control , Dieta , Ingeniería Metabólica , Carotenoides , Enfermedad Crónica/prevención & control , Productos Agrícolas/genética , Productos Agrícolas/metabolismo , Enfermedades Carenciales/dietoterapia , Ácidos Grasos Insaturados , Alimentos , Humanos , Valor Nutritivo , Polifenoles , Vitaminas/farmacologíaRESUMEN
Background: Maternal iodine deficiency during pregnancy and lactation is common in Bangladesh.Objective: We evaluated the effect of lipid-based nutrient supplements for pregnant and lactating women (LNS-PL) on urinary iodine concentration (UIC).Methods: We conducted a cluster-randomized controlled effectiveness trial in which we enrolled 4011 pregnant women at ≤20 gestational weeks. Women in 48 clusters received iron and folic acid (IFA; 60 mg Fe/d + 400 µg folic acid/d) and women in 16 clusters received LNS-PL (20 g/d, 118 kcal) containing 22 vitamins and minerals (including 250 µg I). We randomly selected a subsample of 1159 women for repeated urine sample collection, i.e., at enrollment, at 36 wk of gestation, and at 6 mo postpartum, for UIC analysis, a secondary outcome of the trial.Results: The geometric mean UIC at 36 wk of gestation and at 6 mo postpartum did not differ significantly between the IFA and LNS-PL groups. The median (quartile 1, quartile 3) UIC at 36 wk was 27.4 µg/L (16.9, 52.7 µg/L) in the IFA group and 30.2 µg/L (17.7, 56.6 µg/L) in the LNS-PL group; at 6 mo, these were 23.0 µg/L (10.0, 45.9 µg/L) in the IFA group and 22.2 µg/L (9.1, 50.4 µg/L) in the LNS-PL group.Conclusion: Daily consumption of LNS-PL containing 250 µg I did not increase the UICs of pregnant and lactating women in Bangladesh. Iodine from lipid-based nutrient supplements may have been stored in the thyroid gland or secreted in breast milk instead of being excreted in urine. Additional research that uses other biomarkers of iodine status is needed to determine how to meet the iodine requirements of pregnant and lactating women in Bangladesh and similar settings. This trial was registered at clinicaltrials.gov as NCT01715038.
Asunto(s)
Enfermedades Carenciales/dietoterapia , Suplementos Dietéticos , Yodo , Lactancia , Fenómenos Fisiologicos Nutricionales Maternos , Estado Nutricional , Complicaciones del Embarazo , Adolescente , Adulto , Bangladesh , Biomarcadores/orina , Enfermedades Carenciales/metabolismo , Femenino , Humanos , Yodo/deficiencia , Yodo/farmacocinética , Yodo/uso terapéutico , Yodo/orina , Lactancia/metabolismo , Lípidos , Micronutrientes/uso terapéutico , Necesidades Nutricionales , Periodo Posparto , Embarazo , Complicaciones del Embarazo/dietoterapia , Complicaciones del Embarazo/metabolismo , Oligoelementos/deficiencia , Oligoelementos/farmacocinética , Oligoelementos/uso terapéutico , Oligoelementos/orina , Resultado del Tratamiento , Adulto JovenRESUMEN
Background: Few studies have examined the impact of local animal-source foods (ASFs) on the nutritional status of reproductive-age women in developing countries.Objective: We hypothesized that a midmorning snack of local ASF for 6 mo would reduce dietary micronutrient deficiencies [usual intake less than the estimated average requirement (EAR)] and improve blood biomarkers of iron, zinc, and vitamins A and B-12 status among nonpregnant, reproductive-age women in rural Vietnam.Methods: One hundred seventeen women, 18-30 y old, were randomly assigned to receive either an ASF (mean: 144 kcal, 8.9 mg Fe, 2.7 mg Zn, 1050 µg retinoic acid equivalent vitamin A, and 5.5 µg vitamin B-12) or a control snack (mean: 150 kcal, 2.0 mg Fe, 0.9 mg Zn, 0 µg retinoic acid equivalent vitamin A, and 0 µg vitamin B-12) 5 d/wk for 6 mo. Usual nutrient intakes were estimated by repeated 24-h dietary recalls. Blood samples were collected at baseline and 3 and 6 mo. Because of the relation between nutritional status and inflammation, serum C-reactive protein, α-1-acid-glycoprotein, and urinary tract infections (UTIs) were also monitored.Results: Eighty-nine women (47 in the ASF group and 42 controls) completed the study. In the ASF group, intakes of iron and vitamins A and B-12 below the EAR were eliminated, and the prevalence of a low zinc intake was reduced to 9.6% compared with 64.7% in controls (P < 0.001). At 6 mo, a modest increase (P < 0.05) in hemoglobin and iron status occurred in the ASF group compared with the control group, but plasma zinc, retinol, and serum vitamin B-12 concentrations did not differ. UTI relative risk was 3.9 (P < 0.05) among women assigned to the ASF group who had a low whole-body iron status at baseline.Conclusions: Adding a small amount of locally produced ASF to the diets of reproductive-age Vietnamese women improved micronutrient intakes and iron status. However, the increased UTI incidence in women in the ASF group with initially lower iron stores warrants further investigation.
Asunto(s)
Enfermedades Carenciales/dietoterapia , Huevos , Hierro , Carne , Bocadillos , Vitamina A , Vitamina B 12 , Adolescente , Adulto , Anemia Ferropénica/sangre , Anemia Ferropénica/dietoterapia , Animales , Avitaminosis/sangre , Avitaminosis/dietoterapia , Enfermedades Carenciales/sangre , Suplementos Dietéticos , Femenino , Hemoglobinas/metabolismo , Humanos , Hierro/administración & dosificación , Hierro/sangre , Deficiencias de Hierro , Micronutrientes/administración & dosificación , Micronutrientes/sangre , Micronutrientes/deficiencia , Estado Nutricional , Población Rural , Vietnam , Vitamina A/administración & dosificación , Vitamina A/sangre , Deficiencia de Vitamina A/sangre , Deficiencia de Vitamina A/dietoterapia , Vitamina B 12/administración & dosificación , Vitamina B 12/sangre , Deficiencia de Vitamina B 12/sangre , Deficiencia de Vitamina B 12/dietoterapia , Vitaminas/administración & dosificación , Vitaminas/sangre , Adulto Joven , Zinc/administración & dosificación , Zinc/sangre , Zinc/deficienciaRESUMEN
Depression is a common, recurrent, and debilitating illness that has become more prevalent over the past 100 years. This report reviews the etiology and pathophysiology of depression, and explores the role of omega 3 polyunsaturated fatty acids (n-3 PUFA) as a possible treatment. In seeking to understand depression, genetic factors and environmental influences have been extensively investigated. Research has led to several hypotheses for the pathophysiological basis of depression but a definitive pathogenic mechanism, or group thereof, has hitherto remained equivocal. To date, treatment has been based on the monoamine hypothesis and hence, selective serotonin reuptake inhibitors have been the most widely used class of medication. In the last decade, there has been considerable interest in n-3 PUFAs and their role in depression. These fatty acids are critical for development and function of the central nervous system. Increasing evidence from epidemiological, laboratory, and randomized placebo-controlled trials suggests deficiency of dietary n-3 PUFAs may contribute to development of mood disorders, and supplementation with n-3 PUFAs may provide a new treatment option. Conclusions based on systematic reviews and meta-analyses of published trials to date vary. Research into the effects of n-3 PUFAs on depressed mood is limited. Furthermore, results from such have led to conflicting conclusions regarding the efficacy of n-3 PUFAs in affecting reduction in symptoms of depression. PUFAs are generally well tolerated by adults and children although mild gastrointestinal effects are reported. There is mounting evidence to suggest that n-3 PUFAs play a role in depression and deserve greater research efforts.
Asunto(s)
Enfermedades Carenciales/dietoterapia , Depresión/prevención & control , Trastorno Depresivo Mayor/prevención & control , Suplementos Dietéticos , Medicina Basada en la Evidencia , Ácidos Grasos Esenciales/deficiencia , Ácidos Grasos Omega-3/uso terapéutico , Animales , Antidepresivos/uso terapéutico , Enfermedades Carenciales/metabolismo , Enfermedades Carenciales/fisiopatología , Enfermedades Carenciales/psicología , Depresión/tratamiento farmacológico , Depresión/etiología , Depresión/genética , Trastorno Depresivo Mayor/tratamiento farmacológico , Trastorno Depresivo Mayor/etiología , Trastorno Depresivo Mayor/genética , Dieta Occidental/efectos adversos , Dieta Occidental/psicología , Suplementos Dietéticos/efectos adversos , Ácidos Grasos Esenciales/efectos adversos , Ácidos Grasos Esenciales/uso terapéutico , Ácidos Grasos Omega-3/efectos adversos , Femenino , Aceites de Pescado/efectos adversos , Aceites de Pescado/uso terapéutico , Predisposición Genética a la Enfermedad , Humanos , Masculino , Factores SexualesRESUMEN
Iron deficiency is the most prevalent nutritional deficiency, affecting more than 30% of the total world's population. It is a major public health problem in many countries around the world. Over the years various methods have been used with an effort to try and control iron-deficiency anemia. However, there has only been a marginal reduction in the global prevalence of anemia. Why is this so? Iron and zinc are essential trace elements for humans. These metals influence the transport and absorption of one another across the enterocytes and hepatocytes, due to similar ionic properties. This paper describes the structure and roles of major iron and zinc transport proteins, clarifies iron-zinc interactions at these sites, and provides a model for the mechanism of these interactions both at the local and systemic level. This review provides evidence that much of the massive extent of iron deficiency anemia in the world may be due to an underlying deficiency of zinc. It explains the reasons for predominance of cellular zinc status in determination of iron/zinc interactions and for the first time thoroughly explains mechanisms by which zinc brings about these changes.
Asunto(s)
Absorción Fisiológica , Enterocitos/metabolismo , Hepatocitos/metabolismo , Absorción Intestinal , Hierro de la Dieta/metabolismo , Modelos Biológicos , Zinc/metabolismo , Anemia Ferropénica/sangre , Anemia Ferropénica/etiología , Anemia Ferropénica/metabolismo , Anemia Ferropénica/prevención & control , Animales , Proteínas de Transporte de Catión/genética , Proteínas de Transporte de Catión/metabolismo , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/etiología , Enfermedades Carenciales/fisiopatología , Enfermedades Carenciales/prevención & control , Dieta/efectos adversos , Suplementos Dietéticos , Regulación de la Expresión Génica , Humanos , Hierro/sangre , Hierro/química , Hierro/metabolismo , Deficiencias de Hierro , Hierro de la Dieta/antagonistas & inhibidores , Hierro de la Dieta/uso terapéutico , Páncreas/metabolismo , Zinc/química , Zinc/deficiencia , Zinc/uso terapéuticoRESUMEN
Selenium, a "dual-surface" element, maintains a very thin line between a level of necessity and harmfulness. Because of this, a deficiency or excess of this element in an organism is dangerous and causes health-related problems, both physically and mentally. The main source of selenium is a balanced diet, with a proper selection of meat and plant products. Meanwhile, the proper assimilation of selenium into these products depends on their bioavailability, bioaccessibility, and/or bioactivity of a given selenium compound. From the time when it was discovered that selenium and its compounds have a significant influence on metabolic processes and in many countries throughout the world, a low quantity of selenium was found in different parts of the environment, pressure was put upon an effective and fast method of supplementing the environment with the help of selenium. This work describes supplementation methods applied with the use of selenium, as well as new ideas for increasing the level of this element in various organisms. Based on the fact that selenium appears in the environment at trace levels, the determination of total amount of selenium or selenium speciation in a given sample demands the selection of appropriate measurement methods. These methods are most often comprised of a sample preparation technique and/or a separation technique as well as a detection system. The work presents information on the subject of analytical methods used for determining selenium and its compounds as well as examples in literature of their application.
Asunto(s)
Alimentación Animal , Suplementos Dietéticos , Compuestos de Selenio/uso terapéutico , Selenio/uso terapéutico , Alimentación Animal/efectos adversos , Alimentación Animal/análisis , Animales , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/prevención & control , Enfermedades Carenciales/veterinaria , Suplementos Dietéticos/efectos adversos , Análisis de los Alimentos/métodos , Humanos , Valor Nutritivo , Selenio/análisis , Selenio/deficiencia , Selenio/envenenamiento , Compuestos de Selenio/efectos adversos , Compuestos de Selenio/análisis , Compuestos de Selenio/metabolismoRESUMEN
Hypophosphatemia (HP) with or without intracellular depletion of inorganic phosphate (Pi) and adenosine triphosphate has been associated with central and peripheral nervous system complications and can be observed in various diseases and conditions related to respiratory alkalosis, alcoholism (alcohol withdrawal), diabetic ketoacidosis, malnutrition, obesity, and parenteral and enteral nutrition. In addition, HP may explain serious muscular, neurological, and haematological disorders and may cause peripheral neuropathy with paresthesias and metabolic encephalopathy, resulting in confusion and seizures. The neuropathy may be improved quickly after proper phosphate replacement. Phosphate depletion has been corrected using potassium-phosphate infusion, a treatment that can restore consciousness. In severe ataxia and tetra paresis, complete recovery can occur after adequate replacement of phosphate. Patients with multiple risk factors, often with a chronic disease and severe HP that contribute to phosphate depletion, are at risk for neurologic alterations. To predict both risk and optimal phosphate replenishment requires assessing the nutritional status and risk for re-feeding hypophosphatemia. The strategy for correcting HP depends on the severity of the underlying disease and the goal for re-establishing a phosphate balance to limit the consequences of phosphate depletion.
Asunto(s)
Enfermedades Carenciales/dietoterapia , Suplementos Dietéticos , Hipofosfatemia/dietoterapia , Enfermedades del Sistema Nervioso/fisiopatología , Fosfatos/uso terapéutico , Animales , Enfermedades Carenciales/diagnóstico , Enfermedades Carenciales/etiología , Enfermedades Carenciales/terapia , Suplementos Dietéticos/efectos adversos , Humanos , Hipofosfatemia/diagnóstico , Hipofosfatemia/fisiopatología , Hipofosfatemia/terapia , Infusiones Intravenosas , Enfermedades del Sistema Nervioso/sangre , Enfermedades del Sistema Nervioso/etiología , Estado Nutricional , Fosfatos/administración & dosificación , Fosfatos/efectos adversos , Fosfatos/deficiencia , Fósforo/sangre , Guías de Práctica Clínica como Asunto , Síndrome de Realimentación/sangre , Síndrome de Realimentación/etiología , Síndrome de Realimentación/fisiopatología , Síndrome de Realimentación/prevención & control , Índice de Severidad de la EnfermedadRESUMEN
OBJECTIVE: To use proton magnetic resonance spectroscopy ((1)H MRS) to investigate the effects of fish oil (FO) supplementation on cortical metabolite concentrations in adolescents with major depressive disorder (MDD). METHODS: Metabolite concentrations were determined by (1)H MRS in the anterior cingulate cortex and bilateral dorsolateral prefrontal cortex (DLPFC) of adolescents with MDD before and following 10-week open-label supplementation with low (2.4â g/day, n = 7) or high (16.2â g/day, n = 7) dose FO. Depressive symptom severity scores and erythrocyte fatty acid levels were also determined. RESULTS: Baseline erythrocyte eicosapentaenoic acid (EPA) composition was positively correlated, and arachidonic acid (AA) and the AA/EPA ratio were inversely correlated, with choline (Cho) concentrations in the right DLPFC. Docosahexaenoic acid (DHA) composition was inversely correlated with myo-inositol (mI) concentrations in the left DLPFC. Erythrocyte EPA and DHA composition increased, and AA decreased, significantly following low-dose and high-dose FO supplementation. In the intent-to-treat sample, depressive symptom severity scores decreased significantly in the high-dose group (-40%, P < 0.0001) and there was a trend in the low-dose group (-20%, P = 0.06). There were no significant baseline-endpoint changes in metabolite levels in each voxel. In the low-dose group there were changes with large effect sizes, including a decrease in mI in the left DLPFC (-12%, P = 0.18, d = 0.8) and increases in glutamate + glutamine (Glx) (+12%, P = 0.19, d = 0.8) and Cho (+15%, P = 0.08, d = 1.2) in the right DLPFC. In the high-dose group, there was a trend for increases in Cho in the right DLPFC (+10%, P = 0.09, d = 1.2). DISCUSSION: These preliminary data suggest that increasing the LCn-3 fatty acid status of adolescent MDD patients is associated with subtle changes in Glx, mI, and Cho concentrations in the DLPFC that warrant further evaluation in a larger controlled trial.
Asunto(s)
Fenómenos Fisiológicos Nutricionales de los Adolescentes , Enfermedades Carenciales/dietoterapia , Trastorno Depresivo Mayor/prevención & control , Suplementos Dietéticos , Ácidos Grasos Esenciales/uso terapéutico , Aceites de Pescado/uso terapéutico , Adolescente , Adulto , Niño , Fenómenos Fisiológicos Nutricionales Infantiles , Enfermedades Carenciales/metabolismo , Enfermedades Carenciales/fisiopatología , Enfermedades Carenciales/psicología , Trastorno Depresivo Mayor/diagnóstico por imagen , Trastorno Depresivo Mayor/etiología , Trastorno Depresivo Mayor/metabolismo , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Ácidos Grasos Esenciales/deficiencia , Ácidos Grasos Esenciales/metabolismo , Femenino , Aceites de Pescado/administración & dosificación , Giro del Cíngulo/diagnóstico por imagen , Giro del Cíngulo/metabolismo , Humanos , Análisis de Intención de Tratar , Perdida de Seguimiento , Imagen por Resonancia Magnética , Masculino , Neuroimagen , Corteza Prefrontal/diagnóstico por imagen , Corteza Prefrontal/metabolismo , Escalas de Valoración Psiquiátrica , Adulto JovenRESUMEN
Alterations in muscle fatty acid metabolism have been implicated in mediating the severity of insulin resistance. In the insulin resistant heart fatty acids are favored as an energy source over glucose, which is thus associated with increased fatty acid oxidation, and an overall decrease in glycolysis and glucose oxidation. In addition, excessive uptake and beta-oxidation of fatty acids in obesity and diabetes can compromise cardiac function. In animal studies, mice fed a high fat diet (HFD) show cardiac insulin resistance in which the accumulation of intra-myocardial diacylglycerol has been implicated, likely involving parallel signaling pathways. A HFD also results in accumulation of fatty acid oxidation byproducts in muscle, further contributing to insulin resistance. Carnitine acetyltransferase (CrAT) has an essential role in the cardiomyocyte because of its need for large amounts of carnitine. In the cardiomyocyte, carnitine switches energy substrate preference in the heart from fatty acid oxidation to glucose oxidation. This carnitine-induced switch in fatty acid oxidation to glucose oxidation is due to the presence of cytosolic CrAT and reverse CrAT activity. Accordingly, inhibition of fatty acid oxidation, or stimulation of CrAT, may be a novel approach to treatment of insulin resistance.
Asunto(s)
Carnitina Aciltransferasas/metabolismo , Carnitina/metabolismo , Diabetes Mellitus/metabolismo , Ácidos Grasos no Esterificados/metabolismo , Resistencia a la Insulina , Miocardio/metabolismo , Obesidad/metabolismo , Animales , Carnitina/deficiencia , Carnitina/uso terapéutico , Carnitina Aciltransferasas/química , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/metabolismo , Enfermedades Carenciales/fisiopatología , Enfermedades Carenciales/prevención & control , Diabetes Mellitus/dietoterapia , Diabetes Mellitus/etiología , Diabetes Mellitus/fisiopatología , Dieta Alta en Grasa/efectos adversos , Suplementos Dietéticos , Diglicéridos/metabolismo , Corazón/fisiopatología , Humanos , Músculos/enzimología , Músculos/metabolismo , Miocardio/enzimología , Obesidad/dietoterapia , Obesidad/etiología , Obesidad/fisiopatología , Oxidación-Reducción , Disfunción Ventricular/etiología , Disfunción Ventricular/prevención & controlRESUMEN
Carnitine is needed for transfer of long-chain fatty acids across the inner mitochondrial membrane for subsequent ß-oxidation. Carnitine can be synthesized by the body and is also obtained in the diet through consumption of meat and dairy products. Defects in carnitine transport such as those caused by defective activity of the OCTN2 transporter encoded by the SLC22A5 gene result in primary carnitine deficiency, and newborn screening programmes can identify patients at risk for this condition before irreversible damage. Initial biochemical diagnosis can be confirmed through molecular testing, although direct study of carnitine transport in fibroblasts is very useful to confirm or exclude primary carnitine deficiency in individuals with genetic variations of unknown clinical significance or who continue to have low levels of carnitine despite negative molecular analyses. Genetic defects in carnitine biosynthesis do not generally result in low plasma levels of carnitine. However, deletion of the trimethyllysine hydroxylase gene, a key gene in carnitine biosynthesis, has been associated with non-dysmorphic autism. Thus, new roles for carnitine are emerging that are unrelated to classic inborn errors of metabolism.
Asunto(s)
Cardiomiopatías/diagnóstico , Carnitina/deficiencia , Enfermedades Carenciales/diagnóstico , Pruebas Genéticas , Hiperamonemia/diagnóstico , Errores Innatos del Metabolismo/diagnóstico , Enfermedades Musculares/diagnóstico , Mutación , Tamizaje Neonatal , Miembro 5 de la Familia 22 de Transportadores de Solutos/genética , Cardiomiopatías/dietoterapia , Cardiomiopatías/epidemiología , Cardiomiopatías/metabolismo , Carnitina/metabolismo , Carnitina/uso terapéutico , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/metabolismo , Dinamarca/epidemiología , Suplementos Dietéticos , Humanos , Hiperamonemia/dietoterapia , Hiperamonemia/epidemiología , Hiperamonemia/metabolismo , Incidencia , Recién Nacido , Errores Innatos del Metabolismo/dietoterapia , Errores Innatos del Metabolismo/genética , Errores Innatos del Metabolismo/metabolismo , Oxigenasas de Función Mixta/deficiencia , Oxigenasas de Función Mixta/genética , Oxigenasas de Función Mixta/metabolismo , Enfermedades Musculares/dietoterapia , Enfermedades Musculares/epidemiología , Enfermedades Musculares/metabolismo , Pronóstico , Miembro 5 de la Familia 22 de Transportadores de Solutos/deficiencia , Miembro 5 de la Familia 22 de Transportadores de Solutos/metabolismoRESUMEN
While the increased rates of survival in childhood cancers have increased progressively in recent decades, many childhood cancer survivors will have at least one chronic health condition within 40 years of age. In this regard, cardiovascular complications have emerged as a leading cause of long-term morbidity and mortality in long-term survivors of childhood cancer, likely due to exposure to anthracycline chemotherapy, and outcomes in patients with anthracycline-related cardiomyopathy remain poor. Some progress has been made in understanding the mechanisms at the basis of anthracycline-related cardiomyopathy, which appear to involve generation of reactive oxygen species, leading to mitochondrial dysfunction, followed by myocyte apoptosis and maladaptive left ventricular remodeling. Even if several guidelines currently exist for monitoring cancer patients treated with cardiotoxic therapies who are at high risk for heart failure, much work remains to be done in finding reliable markers for screening for cardiac dysfunction. Studies from our group have identified alterations in L-carnitine in cancer survivors. While additional investigations are needed, preliminary studies suggest a role for carnitine in primary prevention (during treatment) and secondary prevention (to improve function after treatment).
Asunto(s)
Antraciclinas/efectos adversos , Antineoplásicos/efectos adversos , Cardiomiopatías/inducido químicamente , Cardiotoxicidad/metabolismo , Corazón/efectos de los fármacos , Antraciclinas/uso terapéutico , Antineoplásicos/uso terapéutico , Cardiomiopatías/dietoterapia , Cardiomiopatías/metabolismo , Cardiomiopatías/prevención & control , Cardiotoxicidad/dietoterapia , Cardiotoxicidad/fisiopatología , Cardiotoxicidad/prevención & control , Carnitina/deficiencia , Carnitina/metabolismo , Carnitina/uso terapéutico , Niño , Enfermedades Carenciales/inducido químicamente , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/metabolismo , Enfermedades Carenciales/prevención & control , Suplementos Dietéticos , Corazón/fisiopatología , Humanos , Miocardio/metabolismo , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismoRESUMEN
The 1st International Carnitine Working Group concluded with a round table discussion addressing several areas of relevance. These included the design of future studies that could increase the amount of evidence-based data about the role of carnitine in the treatment of fatty acid oxidation defects, for which substantial controversy still exists. There was general consensus that future trials on the effect of carnitine in disorders of fatty acid oxidation should be randomized, double-blinded, multicentered and minimally include the following diagnoses: medium-chain acyl coenzyme A (CoA) dehydrogenase deficiency, very long-chain acyl-CoA dehydrogenase deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and mitochondrial trifunctional protein deficiency. Another area that generated interest was trials of carnitine in cardiomyopathy and, especially, the use of biomarkers to identify patients at greater risk of cardiotoxicity following treatment with anthracyclines. The possibility that carnitine treatment may lead to improvements in autistic behaviors was also discussed, although the evidence is still not sufficient to make any firm conclusions in this regard. Preliminary data on carnitine levels in children and adolescents with primary hypertension, low birth weight and nephrotic syndrome was also presented. Lastly, the panelists stressed that there remains an objective need to harmonize the terminology used to describe carnitine deficiencies (e.g., primary, secondary and systemic deficiency).
Asunto(s)
Investigación Biomédica/métodos , Carnitina/uso terapéutico , Enfermedades Carenciales/prevención & control , Suplementos Dietéticos , Medicina Basada en la Evidencia , Adolescente , Trastorno Autístico/dietoterapia , Trastorno Autístico/metabolismo , Investigación Biomédica/tendencias , Cardiomiopatías/dietoterapia , Cardiomiopatías/metabolismo , Carnitina/deficiencia , Carnitina/metabolismo , Niño , Congresos como Asunto , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/metabolismo , Enfermedades Carenciales/fisiopatología , Humanos , Hiperamonemia/dietoterapia , Hiperamonemia/metabolismo , Hipertensión/dietoterapia , Hipertensión/etiología , Hipertensión/metabolismo , Hipertensión/prevención & control , Internacionalidad , Errores Innatos del Metabolismo/dietoterapia , Errores Innatos del Metabolismo/metabolismo , Enfermedades Musculares/dietoterapia , Enfermedades Musculares/metabolismo , Síndrome Nefrótico/dietoterapia , Síndrome Nefrótico/metabolismo , Síndrome Nefrótico/prevención & control , Sociedades MédicasRESUMEN
The metabolic roles of carnitine have been greatly clarified over the past 50 years, and it is now well established that carnitine is a key player in mitochondrial generation of energy and metabolism of acetyl coenzyme A. A therapeutic role for carnitine in treatment of nutritional deficiencies in infants and children was first demonstrated in 1958, and since that time it has been used to treat a number of inborn errors of metabolism. Carnitine was approved by the US Food and Drug Administration in 1985 for treatment of 'primary carnitine deficiency', and later in 1992 for treatment of 'secondary carnitine deficiency', a definition that included the majority of relevant metabolic disorders associated with low or abnormal plasma carnitine levels. Today, carnitine treatment of inborn errors of metabolism is a safe and integral part of many treatment protocols, and a growing interest in carnitine has resulted in greater recognition of many causes of carnitine depletion. Notwithstanding, there is still a lack of data from randomized clinical trials, even on the use of carnitine in inborn errors of metabolism, although ethical issues may be a contributing factor in this regard.
Asunto(s)
Cardiomiopatías/prevención & control , Carnitina/deficiencia , Carnitina/uso terapéutico , Ciencias de la Nutrición del Niño/historia , Enfermedades Carenciales/prevención & control , Suplementos Dietéticos , Hiperamonemia/prevención & control , Errores Innatos del Metabolismo/dietoterapia , Enfermedades Musculares/prevención & control , Ciencias de la Nutrición/historia , Administración Intravenosa , Adulto , Cardiomiopatías/dietoterapia , Cardiomiopatías/historia , Cardiomiopatías/fisiopatología , Carnitina/administración & dosificación , Carnitina/efectos adversos , Carnitina/historia , Carnitina Aciltransferasas/deficiencia , Carnitina Aciltransferasas/historia , Niño , Ensayos Clínicos como Asunto , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/historia , Enfermedades Carenciales/fisiopatología , Suplementos Dietéticos/efectos adversos , Metabolismo Energético , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Hiperamonemia/dietoterapia , Hiperamonemia/historia , Hiperamonemia/fisiopatología , Lactante , Errores Innatos del Metabolismo Lipídico/dietoterapia , Errores Innatos del Metabolismo Lipídico/tratamiento farmacológico , Errores Innatos del Metabolismo Lipídico/historia , Errores Innatos del Metabolismo Lipídico/fisiopatología , Errores Innatos del Metabolismo/tratamiento farmacológico , Errores Innatos del Metabolismo/historia , Errores Innatos del Metabolismo/fisiopatología , Enfermedades Musculares/dietoterapia , Enfermedades Musculares/historia , Enfermedades Musculares/fisiopatología , Producción de Medicamentos sin Interés Comercial/historiaRESUMEN
Optimal nutrition is critical to the attainment of healthy growth, human capital and sustainable development. In Egypt, infants and young children face overlapping forms of malnutrition, including micronutrient deficiencies, stunting and overweight. Yet, in this setting, little is known about the factors associated with growth during the first year of life. A rise in stunting in Lower Egypt from 2005 to 2008 prompted this implementation research study, which followed a longitudinal cohort of infants from birth to 1 year of age within the context of a USAID-funded maternal and child health integrated programme. We sought to determine if growth patterns and factors related to early growth differed in Lower and Upper Egypt, and examined the relationship between weight loss and subsequent stunting at 12 months of age. Growth patterns revealed that length-for-age z-score (LAZ) decreased and weight-for-length z-score (WLZ) increased from 6 to 12 months of age in both regions. One-quarter of infants were stunted and nearly one-third were overweight by 12 months of age in lower Egypt. Minimum dietary diversity was significantly associated with WLZ in Lower Egypt (ß = 0.22, P < 0.05), but not in Upper Egypt. Diarrhoea, fever and programme exposure were not associated with any growth outcome. Weight loss during any period was associated with a twofold likelihood of stunting at 12 months in Lower Egypt, but not Upper Egypt. In countries, like Egypt, facing the nutrition transition, infant and young child nutrition programmes need to address both stunting and overweight through improving dietary quality and reducing reliance on energy-dense foods.
Asunto(s)
Desarrollo Infantil , Dieta/efectos adversos , Asistencia Alimentaria , Transición de la Salud , Fenómenos Fisiológicos Nutricionales del Lactante , Desnutrición/epidemiología , Sobrepeso/epidemiología , Algoritmos , Estatura , Peso Corporal , Estudios de Cohortes , Enfermedades Carenciales/complicaciones , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/epidemiología , Egipto/epidemiología , Femenino , Trastornos del Crecimiento/epidemiología , Trastornos del Crecimiento/etiología , Trastornos del Crecimiento/prevención & control , Humanos , Lactante , Recién Nacido , Estudios Longitudinales , Masculino , Desnutrición/complicaciones , Desnutrición/dietoterapia , Desnutrición/fisiopatología , Micronutrientes/deficiencia , Sobrepeso/etiología , Sobrepeso/prevención & control , PrevalenciaRESUMEN
Antenatal iron and multiple micronutrient supplementation has been shown in randomized trials to improve birthweight, although mechanisms are unknown. We examined late pregnancy serum erythropoietin (EPO) and cortisol concentrations in relation to maternal micronutrient supplementation and iron status indicators (haemoglobin, serum ferritin, soluble transferrin receptor) in 737 rural Nepalese women to explore evidence of stress or anaemia-associated hypoxia. A double-masked randomized control trial was conducted from December 1998 to April 2001 in Sarlahi, Nepal, in which women received vitamin A alone (as control), or with folic acid (FA), FA + iron, FA + iron + zinc and a multiple micronutrient supplement. In a substudy, we collected maternal blood in the first and third trimester for biochemical assessments. Generalized estimating equations linear regression analysis was used to examine treatment group differences. EPO was â¼ 14-17 mIU mL(-1) lower (P < 0.0001) in late pregnancy in groups receiving iron vs. the control group, with no difference in the FA-only group. Cortisol was 1.3 µg dL(-1) lower (P = 0.04) only in the micronutrient supplement group compared with the control group. EPO was most strongly associated with iron status indicators in groups that did not receive iron, and in the non-iron groups cortisol was positively correlated with EPO (r = 0.15, P < 0.01) and soluble transferrin receptor (sTfR, r = 0.19, P < 0.001). In adjusted analyses, third trimester EPO was associated with a reduction in low birthweight, whereas cortisol was negatively associated with length of gestation and higher risk of preterm birth. Iron and multiple micronutrient supplementation may enhance birth outcomes by reducing mediators of maternal stress and impaired erythropoiesis.
Asunto(s)
Anemia Ferropénica/prevención & control , Suplementos Dietéticos , Hierro de la Dieta/uso terapéutico , Fenómenos Fisiologicos Nutricionales Maternos , Micronutrientes/uso terapéutico , Nacimiento Prematuro/prevención & control , Salud Rural , Adulto , Anemia Ferropénica/sangre , Anemia Ferropénica/dietoterapia , Anemia Ferropénica/epidemiología , Biomarcadores/sangre , Enfermedades Carenciales/sangre , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/epidemiología , Enfermedades Carenciales/prevención & control , Países en Desarrollo , Método Doble Ciego , Eritropoyetina/sangre , Femenino , Humanos , Hidrocortisona/sangre , Nepal/epidemiología , Embarazo , Primer Trimestre del Embarazo , Tercer Trimestre del Embarazo , Nacimiento Prematuro/sangre , Nacimiento Prematuro/dietoterapia , Nacimiento Prematuro/epidemiología , Riesgo , Adulto JovenRESUMEN
Although cross-sectional studies have shown a positive association between Se and cholesterol concentrations, a recent randomised controlled trial in 501 elderly UK individuals of relatively low-Se status found that Se supplementation for 6 months lowered total plasma cholesterol. The Danish PRECISE (PREvention of Cancer by Intervention with Selenium) pilot study (ClinicalTrials.gov ID: NCT01819649) was a 5-year randomised, double-blinded, placebo-controlled trial with four groups (allocation ratio 1:1:1:1). Men and women aged 60-74 years (n 491) were randomised to 100 (n 124), 200 (n 122) or 300 (n 119) µg Se-enriched yeast or matching placebo-yeast tablets (n 126) daily for 5 years. A total of 468 participants continued the study for 6 months and 361 participants, equally distributed across treatment groups, continued for 5 years. Plasma samples were analysed for total and HDL-cholesterol and for total Se concentrations at baseline, 6 months and 5 years. The effect of different doses of Se supplementation on plasma lipid and Se concentrations was estimated by using linear mixed models. Plasma Se concentration increased significantly and dose-dependently in the intervention groups after 6 months and 5 years. Total cholesterol decreased significantly both in the intervention groups and in the placebo group after 6 months and 5 years, with small and nonsignificant differences in changes in plasma concentration of total cholesterol, HDL-cholesterol, non-HDL-cholesterol and total:HDL-cholesterol ratio between intervention and placebo groups. The effect of long-term supplementation with Se on plasma cholesterol concentrations or its sub-fractions did not differ significantly from placebo in this elderly population.
Asunto(s)
Anticolesterolemiantes/uso terapéutico , Enfermedades Cardiovasculares/prevención & control , Colesterol/sangre , Enfermedades Carenciales/dietoterapia , Suplementos Dietéticos , Fenómenos Fisiológicos Nutricionales del Anciano , Selenio/uso terapéutico , Anciano , Anticolesterolemiantes/administración & dosificación , Anticolesterolemiantes/efectos adversos , Anticolesterolemiantes/sangre , Enfermedades Cardiovasculares/etiología , Estudios Transversales , Enfermedades Carenciales/sangre , Enfermedades Carenciales/fisiopatología , Dinamarca/epidemiología , Suplementos Dietéticos/efectos adversos , Método Doble Ciego , Estudios de Factibilidad , Femenino , Humanos , Análisis de Intención de Tratar , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Pacientes Desistentes del Tratamiento , Factores de Riesgo , Selenio/efectos adversos , Selenio/sangre , Selenio/deficiencia , Factores de Tiempo , Levadura Seca/efectos adversos , Levadura Seca/químicaRESUMEN
Both Fe deficiency and poor n-3 fatty acid status have been associated with behavioural changes in children. In the present study, we investigated the effects of Fe and DHA+EPA supplementation, alone or in combination, on physical activity during school days and on teacher-rated behaviour in healthy Fe-deficient school children. In a 2 × 2 factorial design, children (n 98, 6-11 years) were randomly assigned to receive (1) Fe (50 mg) plus DHA (420 mg)+EPA (80 mg), (2) Fe plus placebo, (3) placebo plus DHA+EPA or (4) placebo plus placebo as oral supplements (4 d/week) for 8.5 months. Physical activity was measured during four school days at baseline and endpoint using accelerometers, and data were stratified into morning class time (08.00-10.29 hours), break time (10.30-11.00 hours) and after-break class time (11.01-12.00 hours) for analysis. Classroom behaviour was assessed at endpoint using Conners' Teacher Rating Scales. DHA+EPA supplementation decreased physical activity counts during morning class time, increased sedentary physical activity, and decreased light- and moderate-intensity physical activities. Consistently, DHA+EPA supplementation increased sedentary physical activity and decreased light-intensity physical activity during after-break class time. Even though there were no treatment effects found on teacher-rated behaviour, lower physical activity during morning class time was associated with lower levels of teacher-rated hyperactivity and oppositional behaviour at endpoint. Despite a positive association between Fe status and physical activity during break time at baseline, Fe supplementation did not affect physical activity during break time and class time. Our findings suggest that DHA+EPA supplementation may decrease physical activity levels during class time, and further indicate that accelerometry might be a useful tool to assess classroom behaviour in healthy children.
Asunto(s)
Anemia Ferropénica/dietoterapia , Trastorno por Déficit de Atención con Hiperactividad/prevención & control , Enfermedades Carenciales/dietoterapia , Suplementos Dietéticos , Ácidos Grasos Esenciales/deficiencia , Ácidos Grasos Omega-3/uso terapéutico , Hierro de la Dieta/uso terapéutico , Actigrafía , Anemia Ferropénica/complicaciones , Anemia Ferropénica/fisiopatología , Trastorno por Déficit de Atención con Hiperactividad/etiología , Cápsulas , Niño , Conducta Infantil , Fenómenos Fisiológicos Nutricionales Infantiles , Enfermedades Carenciales/complicaciones , Enfermedades Carenciales/fisiopatología , Suplementos Dietéticos/efectos adversos , Método Doble Ciego , Ácidos Grasos Omega-3/efectos adversos , Femenino , Humanos , Hierro de la Dieta/efectos adversos , Masculino , Actividad Motora , Instituciones Académicas , Sudáfrica , ComprimidosRESUMEN
The objective of the present study was to assess the impact of providing small-quantity lipid-based nutrient supplements (SQ-LNS) on the I status of young Burkinabe children. In total, thirty-four communities were assigned to intervention (IC) or non-intervention cohorts (NIC). IC children were randomly assigned to receive 20 g lipid-based nutrient supplements (LNS)/d containing 90 µg I with 0 or 10 mg Zn from 9 to 18 months of age, and NIC children received no SQ-LNS. All the children were exposed to iodised salt through the national salt iodization programme. Spot urinary iodine (UI), thyroid-stimulating hormone (TSH) and total thyroxine (T4) in dried blood spots as well as plasma thyroglobulin (Tg) concentrations were assessed at 9 and 18 months of age among 123 IC and fifty-six NIC children. At baseline and at 18 months, UI, TSH and T4 did not differ between cohorts. Tg concentration was higher in the NIC v. IC at baseline, but this difference did not persist at 18 months of age. In both cohorts combined, the geometric mean of UI was 339·2 (95% CI 298·6, 385·2) µg/l, TSH 0·8 (95% CI 0·7, 0·8) mU/l, T4 118 (95 % CI 114, 122) nmol/l and Tg 26·0 (95% CI 24·3, 27·7) µg/l at 18 months of age. None of the children had elevated TSH at 18 months of age. Marginally more children in NIC (8·9%) had low T4 (15 ppm). A reduction of SQ-LNS I content could be considered in settings with similarly successful salt iodisation programmes.
Asunto(s)
Enfermedades Carenciales/dietoterapia , Suplementos Dietéticos , Fenómenos Fisiológicos Nutricionales del Lactante , Yodo/uso terapéutico , Estado Nutricional , Salud Rural , Cloruro de Sodio Dietético/uso terapéutico , Burkina Faso/epidemiología , Análisis por Conglomerados , Estudios de Cohortes , Enfermedades Carenciales/sangre , Enfermedades Carenciales/epidemiología , Enfermedades Carenciales/orina , Grasas de la Dieta/administración & dosificación , Suplementos Dietéticos/efectos adversos , Femenino , Humanos , Lactante , Yodo/administración & dosificación , Yodo/deficiencia , Yodo/orina , Masculino , Prevalencia , Riesgo , Tiroglobulina/sangre , Tirotropina/sangre , Tiroxina/sangre , Zinc/administración & dosificación , Zinc/efectos adversos , Zinc/deficiencia , Zinc/uso terapéuticoRESUMEN
Intakes of micronutrient-rich foods are low among Indian women of reproductive age. We investigated whether consumption of a food-based micronutrient-rich snack increased markers of blood micronutrient concentrations when compared with a control snack. Non-pregnant women (n 222) aged 14-35 years living in a Mumbai slum were randomised to receive a treatment snack (containing green leafy vegetables, dried fruit and whole milk powder), or a control snack containing foods of low micronutrient content such as wheat flour, potato and tapioca. The snacks were consumed under observation 6 d per week for 12 weeks, compliance was recorded, and blood was collected at 0 and 12 weeks. Food-frequency data were collected at both time points. Compliance (defined as the proportion of women who consumed ≥ 3 snacks/week) was >85 % in both groups. We assessed the effects of group allocation on 12-week nutrient concentrations using ANCOVA models with respective 0-week concentrations, BMI, compliance, standard of living, fruit and green leafy vegetable consumption and use of synthetic nutrients as covariates. The treatment snack significantly increased ß-carotene concentrations (treatment effect: 47·1 nmol/l, 95 % CI 6·5, 87·7). There was no effect of group allocation on concentrations of ferritin, retinol, ascorbate, folate or vitamin B12. The present study shows that locally sourced foods can be made into acceptable snacks that may increase serum ß-carotene concentrations among women of reproductive age. However, no increase in circulating concentrations of the other nutrients measured was observed.